Caris Life Sciences MI Exome
Caris Life Sciences has launched MI Exome, a whole-exome next-generation sequencing-based assay.
The test covers 22,000 genes and detects point mutations, indels, copy number alterations, and about 250,000 exonic, intronic, and intergenic SNPs. MI Exome also includes analysis of tumor mutational burden, microsatellite instability, loss of heterozygosity, and homologous recombination deficiency, and can be used to interrogate bacteria, viruses and fungi, including cancer-related pathogens, to support microbiome analysis. Average turnaround time is less than 14 days. When paired with the Caris Molecular Intelligence profiling services, the test can help detect and characterize cancer to guide individualized treatment decisions, the company said.
Biocept RUO Target Selector Kits
Biocept has announced the availability of new research-use-only kits allowing molecular laboratories to perform some of its Target Selector molecular assays in house on both formalin-fixed paraffin-embedded tissue and circulating tumor DNA samples. The first available kits, for EGFR mutations, are being made available now and additional assays targeting other oncogene mutations are planned for launch in the future, Biocept said.
The firm's Target Selector technology platform utilizes patented "Switch-Blocker" technology to enrich specimens for specific mutations of interest, resulting in high assay sensitivity and specificity. According to the company, this high performance allows detection of minute fractions of mutated DNA in a liquid biopy sample, and could also allow laboratories to eliminate macro-dissection of tumor blocks or provide results with small DNA inputs compared to most tissue-based assays. Target Selector assays can be used in combination with a variety of low-cost analytical platforms including qPCR, Sanger sequencing, microarrays, and mass-spectrometry, in addition to next generation sequencing, the firm said.
Sengenics ImmuKyne Protein Array
Sengenics has launched the ImmuKyne protein array. The array is based on the company's KREX technology for discovering autoantibody biomarker signatures for predicting drug response and severe immune-related adverse events. The new product enables simultaneous screening of more than 300 immunomodulatory autoantigens comprising clinically significant protein classes that may be implicated in acute respiratory distress syndrome (ARDS), such as cytokines, chemokines, and interleukins. All proteins on ImmuKyne are full-length, correctly folded, and functional with both conformational and non-conformational epitopes preserved, which is critical as 90 percent of antibody binding sites are conformational in nature, the company said. The new tool is designed to further COVID-19 research by helping users understand whether autoantibodies play a role in progression to severe disease in COVID-19 patients.
For more new products and services, please visit the New Products page on our website.